LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial
Advances in Therapy · 2026
DOI: 10.1007/s12325-025-03429-8 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Advances in Therapy, 2026. Verfasst von Juying Qian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Atorvastatin, Ezetimibe, Cholesterol, LDL, Anticholesteremic Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Organon.
Abstract (Originalsprache)
INTRODUCTION: Combining ezetimibe (EZ) and statins is recommended for the treatment of elevated low-density lipoprotein-cholesterol (LDL-C). This subgroup analysis evaluated the efficacy of fixed-dose combination (FDC) therapy with EZ and atorvastatin (AS) versus AS monotherapy on attaining LDL-C goals in Chinese patients with very high risk of atherosclerotic cardiovascular disease (ASCVD) grouped by ASCVD risk, age, and sex. METHODS: Data from the phase III, randomized, double-blind study (NCT03768427) compared EZ10/AS10 mg FDC versus AS20 mg (cohort A), and EZ10/AS20 mg FDC versus AS40 mg monotherapy (cohort B) in Chinese patients with uncontrolled hypercholesterolemia. Proportions of patients attaining 2016 Chinese guideline-recommended LDL-C goals (low/medium risk [< 130 mg/dL], high risk [< 100 mg/dL], very high risk [< 70 mg/dL]) were assessed at weeks 6 and 12. Subgroup analyses by ASCVD risk, age (< 65 and ≥ 65 years), and sex were conducted. RESULTS: LDL-C goal attainment was significantly higher with FDCs versus AS monotherapy at week 12 (cohort A: 62.7% vs. 35.1%, P = 0.0009; cohort B: 67.5% vs. 31.0%, P < 0.0001). A greater proportion of patients with very high ASCVD risk attained LDL-C goals with FDCs versus AS monotherapy at week 12 (cohort A: 62.3% vs. 33.9%; cohort B: 69.1% vs. 29.5%). LDL-C goal attainment was higher with FDCs versus individual doses of AS at weeks 6 and 12 in both cohorts, regardless of age or sex. CONCLUSION: FDCs significantly improved LDL-C goal attainment compared to AS monotherapy in patients with very high ASCVD risk. In the subgroups by age and sex, a higher proportion of patients with uncontrolled hypercholesterolemia attained their LDL-C goals. TRIAL REGISTRY: Trial registration number NCT03768427.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Cardiology, Jilin Province People's Hospital, Changchun, Jilin, China.
- Department of Cardiology, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China.
- Cardiac Department, Aerospace Center Hospital, Beijing, China.
- Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
- Medical Affairs, Organon, Chengdu, Sichuan, China.
ORCID-Profile: Juying Qian, Xuelian Zhang, Jiyan Chen, Chunhua Ding, Ping Yang, Li Qing, Yan Liu, Si Si Chen, Junbo Ge
Förderung
- Organon
Zitieren
APA
Qian, J., Zhang, X., Chen, J., Ding, C., Yang, P., Qing, L., Liu, Y., Chen, S. S., & Ge, J. (2026). LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial. Advances in Therapy. https://doi.org/10.1007/s12325-025-03429-8
Vancouver
Qian J, Zhang X, Chen J, Ding C, Yang P, Qing L, et al. LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial. Advances in Therapy. 2026. doi:10.1007/s12325-025-03429-8
BibTeX
@article{Qian2026,
author = {Qian, Juying and Zhang, Xuelian and Chen, Jiyan and Ding, Chunhua and Yang, Ping and Qing, Li and Liu, Yan and Chen, Si Si and Ge, Junbo},
title = {LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial},
journal = {Advances in Therapy},
year = {2026},
doi = {10.1007/s12325-025-03429-8}
}
EUVIMED